Study on Adding Total Ablative Therapy to Standard Treatment for Limited Metastatic Colorectal Cancer (ERASur Study)

Program Overview

This study is testing if adding a treatment called total ablative therapy to the usual drug treatment can help control colorectal cancer that has spread to a few areas in the body. Normally, patients receive drugs through a vein or by mouth to stop the cancer from growing or spreading. Total ablative therapy aims to destroy cancer at specific sites using focused radiation, surgery, or heat. These methods have been tested for safety, but it's not yet proven if they are beneficial for this stage of cancer. The study will see if this approach can shrink or remove tumors or prevent them from coming back.

Description

The main goal of this study is to see if adding total ablative therapy to standard drug treatment can help patients with newly diagnosed limited metastatic colorectal cancer live longer. The study will also look at how long patients stay free from cancer events, the side effects of the treatments, and how long it takes for cancer to return after treatment.

Participants will be randomly assigned to one of two groups:

• Group 1: Will receive total ablative therapy, which includes focused radiation, surgery, or heat treatment, along with standard chemotherapy. They will also have regular scans to monitor their progress.
• Group 2: Will receive standard chemotherapy and regular scans to monitor their progress.

The study will compare the outcomes of these two groups to see if the additional therapy offers any benefits.

Eligibility Criteria

Locations